Multicenter clinical audit demonstrates real-world hyperkalemia management with sodium zirconium cyclosilicate in Asian hemodialysis patients, highlighting effective therapy beyond phase 3 trials.
Hyperkalemia, a common condition among hemodialysis (HD) patients, is associated with adverse health outcomes. Evidence of the safety and efficacy of a potassium-binder, sodium zirconium cyclosilicate (SZC), has been limited among Asian (HD) patients beyond phase 3 trials. This article demonstrates real-world evidence of SZC usage in an Asian cohort of HD patients.
No takes yet. Share an insight, caveat, or question.
Behram Ali Khan (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: